2025-07-20 - Analysis Report
Okay, here's the report analyzing Merck & Co Inc (MRK) based on the provided data.

## Merck & Co Inc (MRK) Stock Analysis

Merck & Co Inc is a global pharmaceutical company that discovers, develops, manufactures, and markets a wide range of innovative products.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** -4.11%
*   **VOO Cumulative Return:** 96.72%
*   **Absolute Deviation:** -100.84% (MRK significantly underperformed the S&P 500 over the period.)
*   **Relative Deviation:** 0.0 (Based on historical deviations, MRK is currently at the lower end of its performance range compared to the S&P 500.)

**Alpha/Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
|------------|--------|-------|---------|--------|--------|
| 2015-2017  | 5.0%   | 58.2% | -24.0%  | -0.0   | 134.8  |
| 2016-2018  | 43.0%  | 66.4% | 25.0%   | -0.1   | 183.1  |
| 2017-2019  | 40.0%  | 66.4% | 11.0%   | 0.3    | 217.9  |
| 2018-2020  | 20.0%  | 66.4% | 0.0%    | 0.3    | 196.0  |
| 2019-2021  | -1.0%  | 65.6% | -50.0%  | 0.3    | 192.4  |
| 2020-2022  | 13.0%  | 69.5% | 11.0%   | 0.3    | 278.6  |
| 2021-2023  | 31.0%  | 69.5% | 13.0%   | 0.3    | 273.8  |
| 2022-2024  | -7.0%  | 69.5% | -33.0%  | 0.2    | 249.8  |
| 2023-2025  | -56.0% | 61.4% | -105.0% | 0.5    | 200.8  |

**Analysis:**

*   The CAGR (Compound Annual Growth Rate) shows significant volatility over the years, with recent years showing negative growth.
*   MDD (Maximum Drawdown) remains consistently high, indicating significant potential losses.
*   Alpha is largely negative, especially in recent periods, indicating underperformance relative to the market.
*   Beta values are relatively low, suggesting MRK's price is less sensitive to market movements than the S&P 500.

### 2. Recent Stock Price Movements

*   **Current Price:** 79.96
*   **Previous Close:** 81.52
*   **Change:** -1.91
*   **5-Day Moving Average:** 81.82
*   **20-Day Moving Average:** 81.17
*   **60-Day Moving Average:** 79.77

**Analysis:**

*   The stock price closed lower than the previous day, with a negative change.
*   The price is currently below both the 5-day and 20-day moving averages, suggesting a short-term downward trend.
*   The price is slightly above the 60-day moving average, indicating a potential support level.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3399 (Low Risk)
*   **RSI:** 53.21 (Neutral)
*   **PPO:** -0.207 (Bearish)
*   **Hybrid Signal:** Cash 0%, Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **20-Day Relative Deviation Change:** -3.3 (Short-term decline)
*   **Expected Return:** -1127.7% (Significantly negative expected return compared to S&P 500 over a 2+ year investment horizon.)

**Analysis:**

*   The MRI indicates low market risk.
*   The RSI is neutral, suggesting neither overbought nor oversold conditions.
*   The PPO is slightly negative, hinting at a potential bearish trend.
*   The hybrid signal recommends a cautious approach, suggesting to buy 80% of cash.
*   The recent decline in relative deviation and the significantly negative expected return raise concerns about future performance.
*   The negative price change from the last market close (-1.91) confirms current negative price action.

### 4. Recent News & Significant Events

*   **[2025-07-20]:** Merck & Co Inc (MRK) has recently made headlines due to major business developments, regulatory changes, or market events.
*   **[2025-07-19]:** Analysts are discussing Merck & Co Inc's (MRK) recent performance and its outlook in the context of industry trends and global economic factors.
*   **[2025-07-16]:** Merck & Co Inc (MRK)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-17]:** Market experts highlight both risks and opportunities for Merck & Co Inc (MRK), advising investors to monitor recent news and company announcements.

**Analysis:**

*   The recent news suggests potential significant events impacting the stock.
*   Analyst discussions indicate scrutiny of the company's performance and outlook.
*   Volatility is noted, highlighting the importance of monitoring news and announcements.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-05-02 | 2.01  | 15.53 B$    |
| 2024-11-06 | 1.25  | 16.66 B$    |
| 2024-08-05 | 2.15  | 16.11 B$    |
| 2024-05-03 | 1.88  | 15.78 B$    |
| 2025-05-02 | 1.88  | 15.78 B$    |

**Analysis:**

*   Earnings per share (EPS) and revenue have fluctuated over the recent quarters.
*   There is some inconsistency, with the same date showing different EPS and revenue values. (2025-05-02) This should be verified.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | $15.53B   | 77.98%        |
| 2024-12-31 | $15.62B   | 75.50%        |
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |
| 2024-03-31 | $15.78B   | 77.56%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-03-31 | $48.34B   | 10.51%    |
| 2024-12-31 | $46.31B   | 8.08%     |
| 2024-09-30 | $44.50B   | 7.09%     |
| 2024-06-30 | $43.58B   | 12.52%    |
| 2024-03-31 | $40.36B   | 11.80%    |

**Analysis:**

*   Revenue has been relatively stable over the past quarters.
*   Profit margins are high and consistent.
*   Equity has generally increased over time.
*   ROE (Return on Equity) has fluctuated, but generally remains at healthy levels.

### 7. Overall Analysis and Summary

Based on the provided data, Merck & Co Inc (MRK) is currently facing significant challenges.

*   **Underperformance:** MRK has significantly underperformed the S&P 500, with a large negative deviation in cumulative returns.
*   **Technical Indicators:** Short-term trends appear bearish, though the MRI indicates low risk.
*   **Financials:** While revenue, profit margins, equity, and ROE seem stable/healthy, earnings data shows inconsistency that must be verified.
*   **News & Events:** Recent news suggests notable events that might be influencing stock volatility.
*   **Expected Return:** The substantially negative expected return raises serious concerns about the stock's future performance relative to the market.
*   **Recommendations:** Due to the negative trend and uncertainty, a cautious approach is advised. The hybrid signal (Cash 0%, Buy 80% of cash (2 shares - Caution - MRI:0.33)) reflects this prudence. Further research into the specific factors driving the recent underperformance and negative outlook is strongly recommended.
